ACHIEVE LIFE SCIENCES, INC. — Director's Dealing 2011

Jan 6, 2011

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ONCOGENEX PHARMACEUTICALS, INC. (OGXI)
CIK: 0000949858
Period of Report: 2011-01-04

Reporting Person: Cormack Scott Daniel (Director, President and CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2011-01-04	Common Stock	M	6608	$3.889	Acquired	19675	Direct
2011-01-04	Common Stock	S	6608	$16.52	Disposed	13067	Direct
2011-01-04	Common Stock	M	3392	$3.889	Acquired	11484	Indirect
2011-01-04	Common Stock	S	3392	$16.52	Disposed	8092	Indirect
2011-01-05	Common Stock	M	8660	$3.889	Acquired	21727	Direct
2011-01-05	Common Stock	G	8660	$0.00	Disposed	13067	Direct
2011-01-05	Common Stock	G	8660	$0.00	Acquired	44340	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2011-01-04	Stock Options	$3.889	M	6608	Disposed	2011-01-14	Common (6608)	Direct
2011-01-04	Stock Options	$3.889	M	3392	Disposed	2011-01-14	Common (3392)	Indirect
2011-01-05	Stock Options	$3.889	M	8660	Disposed	2011-01-14	Common (8660)	Direct

Footnotes

F1: Scott Cormack and his spouse are the trustees and beneficiaries of the Trycor Investment Trust No. 1

F2: These shares were exercised and sold under the 10b5 Sales Plan.

F3: These shares were exercised under the 10b5 Sales Plan.